Top Tweets for #Rusfertide
Takeda’s MIMRYLO approval unlocks $275m for Protagonist and a $1bn-plus PV bet https://t.co/foWuiyMSVZ $TAK $PTGX #Takeda #ProtagonistTherapeutics #MIMRYLO #Rusfertide #PolycythemiaVera #Hematology #FDA
👏 👏 great news for our patients who suffer from phlebotomy and iron deficiency sx…. A new Era. #rusfertide #PV
👉👉👉Breaking News alert 🚨Sharing the good news of approval for #Rusfertide for patients with Polycythemia Vera PV! A brand new class of drugs — #HepcidinMimetics #MPNSM
Proud to have co-led this effort with Dr @KuykendallMd and our global MPN team!
https://t.co/AnlA8h2ny2
Based on results from the phase 3 #VERIFY trial, the @FDA has approved #rusfertide for the treatment of #erythrocytosis in adult patients with polycythemia vera, introducing the first approved hepcidin mimetic for the disease. Learn more: https://t.co/g4DxUSNQb7
What just happened in Oncology? 5 new drugs/indications ✅ @FDADrugs in August 2026. As a #CommunityOncologists, we need to know them all:
1. #Rusfertide in Polycythemia Vera, improved phlebotomy (76.9% vs. 32.9%)
2. #Daraxonrasib in 2L metastatic pancreatic cancer, mOS 13.2 Vs 6.7mos
3. #Zanidatamab + Chemo ± Tislelizumab in 1L metastatic Her2+ GEA/Gastric adenocarcinoma, mOS 26.4mos Vs 19.2mos
4. #Iberdomide + Dara + Dex in 2L RRMM, improved MRD negativity (41% vs. 21%)
5. #Vusolimogene + Nivo in refractory Melanoma. ORR of 24.2% and mDOR: 14.1mos.
#pancsm #mpnsm #OncTwitter #HemeTwitter @OncoAlert @OncUpdates
🚨#FDA Approval Update | FDA approves a first-in-class treatment for #PolycythemiaVera, a new approach is targeting the biology behind excessive red blood cell production.
#Mimrylo (#rusfertide) is the first approved PV therapy that mimics #hepcidin, a hormone that regulates iron availability. By limiting iron available for red blood cell production, it helps control hematocrit and may reduce the need for frequent blood draws.
🔬In the Phase 3 VERIFY trial:
76.9% of patients on Mimrylo required no phlebotomies vs. 32.9% with placebo
PV can thicken the blood and increase the risk of blood clots, stroke and heart attack. This approval introduces a fundamentally different strategy for managing a rare blood disorder.
#FDAApproval #DrugDiscovery #RareDisease #Hematology #BloodCancer #Pharma #Biotech
A new option in polycythemia vera: the #FDA approved the first-in-class hepcidin mimetic Mimrylo.
In VERIFY, 76.9% vs 32.9% achieved a phlebotomy-free response at weeks 20–32. Thrombosis and survival benefits remain unproven.
#PolycythemiaVera #Rusfertide #Mimrylo #Hematology
👉👉👉Breaking News alert 🚨Sharing the good news of approval for #Rusfertide for patients with Polycythemia Vera PV! A brand new class of drugs — #HepcidinMimetics #MPNSM
Proud to have co-led this effort with Dr @KuykendallMd and our global MPN team!
https://t.co/AnlA8h2ny2
The timing is so interesting: After $SLN data and ahead of the PDUFA. #Rusfertide $ZEAL $RPRX $PTGX $TAK
https://t.co/860GJhTFgw
$PTGX #Rusfertide
Rusfertide in PV — Hepcidin Pathway Therapy 🩸🧲🔥
🧬 Rusfertide = hepcidin mimetic
Works like endogenous hepcidin → regulates systemic iron export.
🔒 Mechanism:
Binds/blocks ferroportin
⬇️ serum iron
⬇️ iron delivery to marrow
⬇️ erythropoiesis
⬇️ Hct/RBC production
🎯 Concept in PV:
Instead of repeatedly removing blood, restrict iron availability to the erythroid marrow.
🧪 Hepcidin-pathway agents in development
🔥 Rusfertide — hepcidin mimetic — Phase 3 VERIFY
🔥 Sapablursen — TMPRSS6 RNA inhibitor — Phase 2/Phase 3 enrolling
🔥 Divesiran / SLN-124 — TMPRSS6 RNAi — Phase 1/2
🔥 DISC-3405 — anti-TMPRSS6 mAb — Phase 2 initiation
🚀 VERIFY Phase 3 trial
Multicenter randomized study in phlebotomy-dependent PV.
👥 Key inclusion:
🩸 ≥3 phlebotomies in prior 28 weeks
or
🩸 ≥5 phlebotomies in prior year
📌 Baseline rusfertide arm:
Median age 58
High-risk PV 64.9%
Concurrent cytoreduction 55.8%
HU 38.8%
IFN 12.9%
JAK inhibitor 3.4%
✅ Week 20–32 primary endpoint
Responders:
Rusfertide 76.9%
Placebo 32.9%
P <0.0001 🔥
🩸 Fewer phlebotomies
Mean phlebotomies:
Rusfertide 0.5
Placebo 1.8
P <0.0001
🎯 Better Hct control
Maintained Hct <45%:
Rusfertide 62.6%
Placebo 14.4%
P <0.0001
🧠 Why this matters
PV phlebotomy removes iron but worsens iron deficiency.
Rusfertide may control erythrocytosis by iron restriction without repeated phlebotomy burden.
🧠 Take-home
Rusfertide is one of the most exciting PV therapies because it targets the iron–hepcidin–erythrocytosis axis, reducing phlebotomy need and improving Hct control in phlebotomy-dependent PV.
#EHA2026 #PolycythemiaVera #PV #MPN #Rusfertide #Hepcidin #IronMetabolism #Phlebotomy #Hematocrit #JAK2 #Hematology #KFSHRC
6️⃣🩺 VERIFY – Polycythemia Vera
•Rusfertide improves response, reduces phlebotomy, enhances Hct control
•✅ Improves fatigue & QoL
•FDA Breakthrough Therapy & Fast Track
#PV #Hematology #ClinicalTrials #Rusfertide
⭐️Clinical Insights-Exciting update for PV treatment‼️
Our experts break down the #Verify trial at #ASH25:
💊 #Rusfertide👉slashes phlebotomy needs, rebuilds iron stores, and ⬆️ QoL!
@KuykendallMd @AaronGerds @TalhaBadarMD @OncBrothers #MedTwitter
https://t.co/wFv9CuF47v
$PTGX #Rusfertide “Practice Changing” -Ph3 VERIFY study data that we’re presented in July by Dr. Andrew Kuykendall from the Moffitt
Cancer Center who highlighted two key takeaways - 1) PV patients have a large symptom
burden that remains a constant throughout their lives that often results in increased
morbidity and mortality associated with thrombotic events and symptoms; 2) Rusfertide
data are practice changing and should be part of standard of care for patients in the near
term. Protagonist expects a BLA for rusfertide to be submitted in 4Q2025 that we believe
should support 2026 regulatory approval and commercial launch. Truist models rusfertide US
peak user-end sales of $1.7B, which is in-line with the peak revenue potential of $1-2B
estimated by the Company.
Dr. Kuykendall reinforced that PV leads to elevated risk of thrombotic events, reduces life
expectancy and is associated with increased fatalities. The goal of PV therapy is to maintain
hematocrit levels <45%, currently achieved via PHL standard of care; however, challenges
with PHL include heterogeneity in hematocrit control, symptomatic iron deficiency, QOL
impact from chronic therapy. Dr. Kuykendall noted case studies where rusfertide could
address key obstacles in PV therapy - 1) Low tolerance of the drug; 2) unable to reach
desired Hct levels; 3) impact on systemic iron levels.
Practice changing results that should become the standard of care for these patients —sharing by Moffitt's Andrew Kuykendall, MD, #Rusfertide (@KuykendallMd) during the #ASCO25 Plenary Session! $PTGX $TAK
Excited to present the 52 wk (part 1a/1b) data from the phase 3 VERIFY study w #rusfertide in pts w PV #MPNSM. 9:30AM. Room W414CD. No better place to be #BiasedOpinion. Some have said talking about hepcidin mimetics gives the same dopamine rush as a cold plunge. #wellness #ASH25
👉👉👉Delighted to present, on behalf of my co-authors , our important longer - term follow-up for the #hepcidin mimetic #Rusfertide from the ph2 clinical trial | #MPNSM | @doctorpemm @KuykendallMd | #ASH25
https://t.co/0xG8LE7pyL
Presenting Effects of Rusfertide for Polycythemia Vera on Behalf of VERIFY Colleagues - @doctorpemm at SOHO 2025
@SocietyofHemOnc
https://t.co/JrErwhQAC3
#Headlines #Health #Hematology #Hemostasis #HemostasisToday #Hepcidin #Medicine #MedEd #PolycythemiaVera #PV #Rusfertide #MedX #SocietyOfHematologicOncology #SOHO2025 #Thrombosis #VERIFY
👉Phase 2 #REVIVE {{2024}} @NEJM , #Rusfertide, a #Hepcidin Mimetic, for Control of #Erythrocytosis in Polycythemia Vera | New England Journal of Medicine @NEJM | #MPNSM | @MKremyanskaya @KuykendallMd @doctorpemm https://t.co/DsVldnu6u8
👉👉👉#SOHO2025 #SOHO25 ||| Thanks 🙏 to @SocietyofHemOnc for the opportunity to present, on behalf of #VERIFY colleagues, our randomized phase 3 results #hepcidin mimetic #Rusfertide for patients with Polycythemia Vera PV #MPNSM |||
🏆 Big moment for MPNs: PV research took the plenary stage at #ASCO2025. Dr. Andrew Kuykendall presented VERIFY trial results on rusfertide:
✓ 62% maintained Hct <45%
✓ Better symptom control
✓ Fewer skin malignancies
#MPNs #PVawareness #Rusfertide #VERIFYtrial
🧬 #ASCO2025 Plenary Haematology In-depth! Dr @KuykendallMd (@MoffittNews) on the VERIFY trial
- 76.9% clinical response with rusfertide
- Better haematocrit control
- Less fatigue, pruritus, night sweats
👀 Watch now https://t.co/7IHRD3SG0k #MediMix #PV #Rusfertide #Hematology
Last Seen Hashtags on Sotwe
teenageer
ชลบุรีนัดเย็ด
Seen from Thailand
Türk ifşa
Seen from Turkey
闪现
Seen from Germany
bigcock22cm
Seen from United Kingdom
porn
omegle filter:videos
Seen from United States
cicigoodreal
Seen from Malaysia
omegle ()
Seen from Brazil
nolimits()***************************************************************************************************************************************************************************
Seen from Turkey
Most Popular Users
Elon Musk 
@elonmusk
241.6M followers
Barack Obama
@barackobama
119M followers
Cristiano Ronaldo
@cristiano
114.1M followers
Donald J. Trump
@realdonaldtrump
111.8M followers
Narendra Modi
@narendramodi
107.2M followers
Rihanna
@rihanna
98.7M followers
NASA
@nasa
92.4M followers
Justin Bieber
@justinbieber
91.8M followers
KATY PERRY
@katyperry
89.8M followers
Taylor Swift
@taylorswift13
83.8M followers
Lady Gaga
@ladygaga
75.3M followers
Virat Kohli
@imvkohli
73M followers
Kim Kardashian
@kimkardashian
70.8M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
66.1M followers
Bill Gates
@billgates
65M followers
Selena Gomez
@selenagomez
62.9M followers
The Ellen Show
@theellenshow
62.3M followers
CNN
@cnn
61.8M followers
X
@x
60.7M followers